CSF1R and Leukoencephalopathy: It is also important to note that some early-onset CSF1R-related leukoencephalopathy patients did not show clinical symptom improvement following HSCT [102], suggesting that selection of the right patients, adequate design of clinical trials for rare diseases and long-term clinical monitoring with standardized, internationally validated tools will be necessary for evaluation of clinical outcomes and experimental treatment endpoints.